The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma

European Journal of Cancer

Volumn 48, Issue 2, 2012, Pages 202-208

  Keizman, Daniel ^a   Ish Shalom, Maya ^a   Huang, Peng ^a   Eisenberger, Mario A ^a   Pili, Roberto ^a   Hammers, Hans ^a   Carducci, Michael A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Metastatic renal cell carcinoma; Neutrophil to lymphocyte ratio; Outcome; Sunitinib

Indexed keywords

SUNITINIB;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DRUG FATALITY; FEMALE; HUMAN; KIDNEY CARCINOMA; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; NEUTROPHIL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL COUNT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; PYRROLES; YOUNG ADULT;

EID: 84655160810     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.09.001     Document Type: Article

References (23)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108 (Pubitemid 40372904)
2. J.S. Lam, J.T. Leppert, A.S. Belldegrun, and R.A. Figlin Novel approaches in the therapy of metastatic renal cell carcinoma World J Urol 23 2005 202 212 (Pubitemid 41136043)
3. R.J. Motzer, N.H. Bander, and D.M. Nanus Renal-cell carcinoma New Engl J Med 335 1996 865 875
4. N.K. Janzen, H.L. Kim, R.A. Figlin, and A.S. Belldegrun Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol Clin North Am 30 2003 843 852 (Pubitemid 37485197)
5. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma NEJM 356 2007 115 124 (Pubitemid 46089672)
6. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill Cancer related inflammation Nature 454 2008 436 444
7. A. Jarnicki, T. Putoczki, and M. Ernst Stat3: Linking inflammation to epithelial Cancer - more than a "gut" felling? Cell Div 5 2010 14
8. Y. Ohno, J. Nakashima, M. Ohori, T. Hatano, and M. Tachibana Pretreatment neutrophil-to- lymphocyte ratio as an independent predictor of recurrence in patients with non-metastatic renal cell carcinoma J Urol 184 2010 873 878
9. S.C. Kao, N. Pavlakis, and R. Harvie High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy Clin Cancer Res 16 2010 5805 5813
10. Y. Kishi, S. Kopetz, and Y.S. Chun Blood neutrophil-to- lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy Ann Surg Oncol 16 2009 614 622
11. X. An, P.R. Ding, and Y.H. Li Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer Biomarkers 15 2010 516 522
12. H. Cho, H.W. Hur, and S.W. Kim Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment Cancer Immunol Immunother 58 2009 15 23
13. T. Yamanaka, S. Matsumoto, and S. Teramukai The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer Oncology 73 2007 215 220 (Pubitemid 351630053)
14. S. Patil, R.A. Figlin, and T.E. Hutson Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma Ann Oncol 22 2011 295 300
15. R.J. Motzer, R.M. Bukowski, and R.A. Figlin Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma Cancer 113 2008 1552 1558
16. T.K. Choueiri, A. Plantade, and P. Elson Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma J Clin Oncol 26 2008 127 131
17. B.I. Rini, D.P. Cohen, and D.R. Lu Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 2011 763 773
18. D.Y. Heng, W. Xie, and M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor- targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
19. D. Keizman, P. Huang, and M.A. Eisenberger Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination Eur J Cancer 47 2011 1955 1961
20. L.A. Fumagalli, J. Vinke, E. Hoff W Ypma, F. Brivio, and A. Nespoli Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy J Immunother 26 2003 394 402 (Pubitemid 37128551)
21. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
22. D. Keizman, O. Rogowski, and S. Berliner Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis Acta Neurol Scand 119 2009 383 389
23. S. Ramsey The role of the systemic inflammatory response as a biomarker in immunotherapy for renal cell carcinoma Mol Diagn Ther 13 5 2009 277 281 [Review]